Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled phase 3 trial
Junichi Nishimura, Masaki Mori(Tokai University), Mamoru Uemura(Osaka International Cancer Institute), Daisuke Sakai(Stowers Institute for Medical Research), Ichiro Takemasa(Osaka International University), Tsunekazu Mizushima(The University of Osaka), Yuichiro� Doki(Osaka Gakuin University), Mitsugu Sekimoto(Kansai Medical University), Yoshihito Ide(Naga Municipal Hospital), Taishi Hata(The University of Osaka), Taroh Satoh(Osaka University Hospital), Yuko Ohno(Hyogo Prefectural Nishinomiya Hospital), Yasuhiro Miyake(High Energy Accelerator Research Organization), Hirofumi Yamamoto(Osaka Gakuin University), Ken Nakata(Sakai Municipal Hospital), Mutsumi Fukunaga(Sakai Municipal Hospital), Masayoshi Yasui(Osaka International Cancer Institute), Hiroyoshi Takemoto(Kinki Central Hospital), Takayuki Fukuzaki, Toshihiro Kudo(Osaka International Cancer Institute), Shunji Morita(Toyonaka Municipal Hospital), Riichiro Nezu(Nishinomiya Municipal Central Hospital)
Cited by 75
Related Papers
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases
|Nature Genetics|2020|599
A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers
|Journal of Thoracic Oncology|2008|424